Real-Life Treatment Paradigms Show Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis
Background. Adalimumab is effective for the maintenance of remission in patients with moderate-to-severe ulcerative colitis (UC). Currently, biologic therapies are used in cases where patients fail conventional medical therapies. If biologic therapies are not available, patients often choose to rema...
Saved in:
| Main Authors: | Candace L. Beilman, Nguyen Xuan Thanh, Victoria Ung, Christopher Ma, Karen Wong, Karen I. Kroeker, Thomas Lee, Haili Wang, Arto Ohinmaa, Phil Jacobs, Brendan P. Halloran, Richard N. Fedorak |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Canadian Journal of Gastroenterology and Hepatology |
| Online Access: | http://dx.doi.org/10.1155/2016/5315798 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Severe Antiphospholipid Syndrome and Diffuse Glomerulonephritis After Adalimumab Treatment in a Patient With Ulcerative Colitis
by: Ileana Rivera-Burgos, et al.
Published: (2024-01-01) -
Pericardial Tamponade in a Patient with Inactive Ulcerative Colitis
by: Ali Rezaie, et al.
Published: (2010-01-01) -
The Impact of Intermediate Antidrug Antibodies to Infliximab and Adalimumab on Clinical Outcomes in Patients with Crohn’s Disease or Ulcerative Colitis
by: Chaoyang Wang, et al.
Published: (2022-03-01) -
Treatment persistence and colectomy-free outcomes in patients with ulcerative colitis receiving golimumab or adalimumab: a UK experience
by: Sami Hoque, et al.
Published: (2020-12-01) -
Increased Risk of Colorectal Cancer in Ulcerative Colitis Patients Diagnosed after 40 Years of Age
by: Constantine J Karvellas, et al.
Published: (2007-01-01)